Latest News

M&As this week: WuXi AppTec, Cachet Pharmaceutical, Shenzhen Neptunus Bioengineering

Chinese pharmaceutical company WuXi AppTec plans to acquire US-based contract research organisation (CRO) ResearchPoint Global...

M&As this week: WuXi AppTec, Cachet Pharmaceutical, Shenzhen Neptunus Bioengineering

Teva submits BLA for fremanezumab to FDA for migraine prevention

Teva Pharmaceutical Industries has submitted a biologics licence application (BLA) for fremanezumab to the US Food and Drug Administration (FDA) for migraine...

Teva submits BLA for fremanezumab to FDA for migraine prevention

Deals this week: Harbin Gloria Pharmaceuticals, F. Hoffmann-La Roche, Intrexon

Chinese pharmaceutical company Harbin Gloria Pharmaceuticals intends to issue medium-term notes due 2019 in a public offering to raise CNY1.6bn...

Deals this week: Harbin Gloria Pharmaceuticals, F. Hoffmann-La Roche, Intrexon

Shanghai Pharma provides update on reports about Cardinal Health deal

Shanghai Pharmaceuticals has issued a clarification on media reports about its acquisition of Cardinal Health’s pharmaceutical distribution business in...

Shanghai Pharma provides update on reports about Cardinal Health deal

Takeda and HemoShear partner to discover new treatments for liver diseases

Takeda and HemoShear partner to discover new treatments for liver diseases

GSK and Plasticell to manufacture haematopoietic cells from iPSC

GSK has entered a collaboration to use UK-based firm Plasticell’s combinatorial stem cell screening technology, CombiCult, to develop haematopoietic cells from induced pluripotent stem cells...

GSK and Plasticell to manufacture haematopoietic cells from iPSC

FDA grants priority review for Exelixis’ Cabometyx to treat advanced RCC

FDA grants priority review for Exelixis’ Cabometyx to treat advanced RCC

Amgen and Boston Children's Hospital to identify new targets for pain syndromes

Amgen has entered a neuroscience research collaboration with Boston Children's Hospital to find new genes and drug targets for severe pain syndromes based on human genetic...

Amgen and Boston Children's Hospital to identify new targets for pain syndromes

Mutabilis joins European ENABLE project to develop new antibiotics

Mutabilis has been selected by the European Gram-negative antibacterial engine (ENABLE) project to focus on the improved development of antibiotics against infections caused by...

Mutabilis joins European ENABLE project to develop new antibiotics

Warp Drive and Roche collaborate to develop new classes of antibiotics

US-based firm Warp Drive Bio has formed a strategic alliance with Roche for the discovery and development of several new classes of...

Warp Drive and Roche collaborate to develop new classes of antibiotics

Genomics and Biogen partner to discover new multiple sclerosis treatments

Genomics and Biogen partner to discover new multiple sclerosis treatments

AstraZeneca’s Faslodex receives CHMP opinion for advanced breast cancer treatment

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for AstraZeneca’s Faslodex (fulvestrant) to treat...

AstraZeneca’s Faslodex receives CHMP opinion for advanced breast cancer treatment

GSK’s Shingrix receives approval in Canada to prevent shingles

GlaxoSmithKline’s (GSK) non-live, recombinant sub-unit, adjuvanted vaccine Shingrix has received approval from Health Canada to prevent shingles (herpes zoster) in people aged 50 or...

GSK’s Shingrix receives approval in Canada to prevent shingles

Shire’s lyophilised Oncaspar receives positive CHMP opinion for ALL in Europe

Irish-headquartered biopharmaceutical company Shire’s lyophilised Oncaspar (pegaspargase) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of...

Shire’s lyophilised Oncaspar receives positive CHMP opinion for ALL in Europe

US NIH launches $215m Partnership for Accelerating Cancer Therapies

US NIH launches $215m Partnership for Accelerating Cancer Therapies

M&As this week: First Coin Capital, China Grand Pharmaceutical and Healthcare Holdings, Tael Management

Canadian technology services company First Coin Capital plans to acquire Bradmer Pharmaceuticals, a pharmaceutical company based in the...

M&As this week: First Coin Capital, China Grand Pharmaceutical and Healthcare Holdings, Tael Management

Deals this week: Catalent Pharma Solutions, China Grand Pharmaceutical and Healthcare Holdings, Recursion Pharmaceuticals

US-based pharmaceutical company Catalent Pharma Solutions plans to raise $450m through the private placement of senior unsecured notes, due...

Deals this week: Catalent Pharma Solutions, China Grand Pharmaceutical and Healthcare Holdings, Recursion Pharmaceuticals

Daiichi Sankyo, Astellas and Mitsubishi Tanabe partner to develop new therapeutics

Daiichi Sankyo, Astellas and Mitsubishi Tanabe partner to develop new therapeutics

Janssen Biotech submits NDA to FDA for apalutamide to treat non-metastatic CRPC

Janssen Biotech has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for apalutamide to treat male patients with non-metastatic castration-resistant...

Janssen Biotech submits NDA to FDA for apalutamide to treat non-metastatic CRPC

AbbVie obtains licence for Turnstone Biologics’ oncolytic viral immunotherapies

AbbVie has entered a research, option and licence agreement with clinical-stage immuno-oncology company Turnstone Biologics for oncolytic viral...

AbbVie obtains licence for Turnstone Biologics’ oncolytic viral immunotherapies

Health Canada accepts marketing application for Mithra’s hormone therapy Tibelia

Health Canada has accepted a marketing authorisation application for the Belgian pharmaceutical company Mithra’s complex therapeutic Tibelia, a tibolone-based product, to be used in hormone...

Health Canada accepts marketing application for Mithra’s hormone therapy Tibelia
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_946450448